About us

Cutting-Edge Technology BY BioXgen

We are here to support you

Welcome to BioXgen

BioXgen is revolutionizing cardiac surgical outcomes through its patent pending medical device, designed and development to prevent or reduce the most common cardiac surgical complications.

We combine state-of-the-art bioscaffold technologies with clinical acumen to develop a novel solution that enhance healing and reduce complications associated with cardiac surgery. Our proprietary platform, based on extracellular matrix (ECM) bioscaffolds and matrix-bound nanovesicles (MBVs), is designed to reduce the damage of heart disease requiring surgery and improve patient recovery outcomes.

Our mission is simple yet profound

BioXgen is set to lead the future of cardiac function through scientific research and clinical expertise.

Reduce negative post-operative outcomes following open heart surgery

Improve post-operative recovery

Extend a patient’s quality of life

Our Founders

BioXgen’s success is built upon the synergy between two visionary leaders:

Their combined expertise in cardiovascular physiology and clinical medicine ensures that our innovations aren’t only scientifically sound but also practically viable and market-ready.

Dr. David Skinner

MD, PHD, MBA
Chief Executive Officer and Co-Founder

Learn More

Dr. John Konhilas

PHD
Chief Scientific Officer and Co-Founder

Learn More

Improved Outcomes

Significantly reducing the incidence of post-operative atrial fibrillation from 30–50% to under 8%, markedly enhancing patient recovery times.

Accelerated Recovery

Faster recovery means patients return home sooner — cutting costs and improving overall outcomes.

Reduced Hospital Stays

Save the hospital and insurance payors significant costs by decreasing resource utilization, minimizing expensive critical inpatient care, and lowering overall healthcare expenditures.

Next-Gen Cardiac Innovation

Pioneering ECM + MBV technology that will transform cardiac surgery outcomes and lead to a new standard for care.

Group 1000002389
Group-93-2 2 (1) 1
Group 93
Group 1000002389
Group-93-2 (1)
Group-93-2 (1)

Dr. David Skinner, MD, PhD, MBA

Chief Executive Officer and Co-Founder

A visionary leader and serial entrepreneur whose innovative spirit and strategic acumen have reshaped the medical industry. As the CEO and President of BioXgen, he spearheads a company dedicated to advancing healthcare solutions, leveraging his extensive expertise and a proven track record of building and scaling transformative enterprises.


With a robust and one-of-a-kind academic foundation, Dr. Skinner first earned his MBA from WP Carey School of Business with an emphasis in finance, further enhancing his already natural business and leadership skills in a formal way. He then earned a combined MD, PhD from the University of Arizona, earning the prestigious Outstanding Achievement Award and completely both degrees in just 5 years. This foundational education shaped his insights and deep understanding of medical science and research and honed his business leadership skills.

Dr. Skinner’s entrepreneurial journey is marked by the creation and successful exit of multiple medical companies. A serial founder, he has a knack for identifying unmet needs in healthcare and building organizations from the ground up to address them. One of his standout achievements was growing a medical company from a carefully selected team of five to a thriving enterprise with 156 employees across nine locations. Every aspect of this organization—from its operational framework to its culture—was designed and developed under his direct leadership. Through strategic partnerships and private equity investment, Dr. Skinner orchestrated a successful exit, cementing his reputation as a builder of high-value, scalable businesses. At BioXgen, Dr. Skinner continues to drive innovation, fostering a culture of excellence and collaboration. His leadership is defined by a relentless pursuit of impactful solutions, blending clinical expertise, business savvy, and a passion for improving lives. Under his guidance, BioXgen is poised to redefine standards in healthcare, building on his legacy of transforming ideas into industry-leading enterprises

Dr. John Konhilas, PhD

Chief Scientific Officer and Co-Founder

Dr. Konhilas holds 11 patents nationally and internationally, has been successful submitting Investigational New Drug applications and Premarket Notification 510(k) applications. Dr. Konhilas’ entrepreneurial spirit is evident in his prior ventures, including roles in translational medicine startups like SciCor, LLC and Menolabs, LLC and holds advisor positions in companies focused on women’s health and cardiovascular therapeutics. He leads our R&D efforts at BioXgen, ensuring our products meet the highest standards of efficacy, and safety, His passion for innovation, guarantees that BioXgen’s solutions are grounded and cutting edge and current science positioning us to revolutionize ECM applications for cardiac disease.

A renowned expert in the cardiovascular physiology and regenerative medicine, Dr. Konhilas is a Professor in the Departments of Physiology, Biomedical Engineering, Cellular and Molecular Medicine, Molecular and Cellular Biology and Nutritional Sciences and a key Scientist in the Sarver Molecular Cardiovascular Research Program at the University of Arizona. With over 30 years of expertise in cardiovascular physiology and clinical medicine, he has dedicated his career to understanding the intricacies of heart disease. Dr. Konhilas has been central to the novel development of ECM-based therapies for cardiac repair. His groundbreaking research has reshaped how we study the impact of sex and menopause on heart disease.

With a PhD in Physiology and Biophysics and MS in Biological Sciences from the University of Illinois and undergraduate degrees in Art and Art History and Neurosciences from Duke University, Dr. Konhilas brings a multidisciplinary perspective to BioXgen. He has authored over 118 publications earned more than 4000 citations and led integrative research projects that bridge basic science with translational applications, his expertise in ECM-based materials and tissue regeneration has been pivotal in developing BioXgen, proprietary ECM formulation which promotes cardiac tissue remodeling and prevents inflammatory responses following cardiac injury.